Articles from Takara Bio USA, Inc.

Takara Bio USA, Inc. (“Takara Bio USA”), a wholly owned subsidiary of Takara Bio Inc. ("Takara Bio"), today announced the launch of the Takara Bio Certified Service Provider (CSP) Program, which equips service providers to conduct customer experiments using advanced NGS and single-cell technologies from Takara Bio such as the Shasta® Single Cell System, a high-throughput single-cell analysis platform. Admera Health, a leading provider of NGS services, is recognized as the first organization to receive certification on the Shasta system, which positions Admera at the forefront of the single-cell genomics industry. With this program, Takara Bio USA is creating a network of trusted providers that have been trained and evaluated to deliver high-quality results, driving scientific progress globally.

Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., and Hamilton Company announced a development and co-marketing agreement to deliver integrated, automated next-generation sequencing (NGS) library preparation workflows to laboratories worldwide.

Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., today announced that it presented a scientific poster at the Advances in Genome Biology and Technology (AGBT) general meeting detailing a new reagent-kit-based spatial transcriptomics workflow developed in collaboration with Illumina. Combining Takara Bio USA’s Trekker Single-Cell Spatial Mapping Kit with the Illumina Single Cell 3′ RNA Prep assay, users of Illumina solutions will be able to obtain high-density, high-sensitivity spatial maps with true single-cell resolution. The AGBT general meeting takes place in Orlando, Florida on February 23–26, 2026.

Takara Bio USA, Inc. (“Takara Bio USA”), a wholly owned subsidiary of Takara Bio Inc. ("Takara Bio"), today announced a series of updates to its spatial biology product portfolio, extending its innovation with a new class of spatial technology. Takara Bio USA has expanded its instrument-free Trekker™ Single-Cell Spatial Mapping Kits for compatibility with formalin-fixed paraffin-embedded (FFPE) samples, one of the most common and trusted archival sample types, making spatial single-cell analysis more accessible to a broader range of researchers. The Trekker kits have also been enhanced for compatibility with additional research workflows and third-party instrument systems, including single-cell library prep platforms from 10x Genomics, BD Biosciences, Parse Biosciences, and Illumina.

Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., today announced the launch of the SmartChip ND™ Real-Time PCR System, an automated, research-use-only (RUO), high-throughput qPCR solution for infectious disease research. Takara Bio USA is now accepting orders of the SmartChip ND Real-Time PCR System.

Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., today announced the launch of the SmartChip ND™ Real-Time PCR System, an automated, research-use-only (RUO), high-throughput qPCR solution for monitoring antimicrobial resistance (AMR), supporting efforts to ensure environmental safety and sustainability. The flexible system covers a variety of configurations, enabling users to run broad surveillance panels. The platform can process up to 5,184 reactions per chip in less than 30 minutes of direct hands-on time. Each nanoliter-scale reaction reduces variability by eliminating the need for preamplification and reduces costs due to decreased reagent volumes. Takara Bio USA is now accepting orders of the SmartChip ND Real-Time PCR System for shipment in Q4.

Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., today announced the launch of the Lenti-X™ Transduction Sponge, a first-to-market dissolvable microfluidic transduction enhancer that innovates in vitro lentivirus-mediated gene delivery techniques. With an easy, walkaway workflow, the Lenti-X Transduction Sponge achieves high transduction efficiency in any cell type, enabling downstream research applications in the gene and cell therapy space.

Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., today announced the launch of the Shasta™ Single-Cell System, an automated, high-throughput NGS solution with well-validated chemistries and intuitive bioinformatics tools that enables novel biomarker discovery for oncology research. This complete system allows researchers to mine more genomic and transcriptomic information from many more cells than possible with current technologies, while saving time and costs for research groups. Existing whole-genome amplification (WGA) technologies currently process 96–384 single cells per plate; the Shasta system increases WGA throughput to 1,500 cells per run. With its total RNA-seq application, the Shasta system detects more RNA biotypes with high sensitivity at high throughput—up to 100,000 cells per run—which is an improvement over both plate-based full-length RNA-seq and high-throughput mRNA-seq methods.

Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., today announced plans to launch two critical solutions for oncology research. These automated single-cell total RNA-seq and DNA-seq library preparation kits will provide high sample and cell throughput, less hands-on time, and the ability to capture more information than other available technologies. The Shasta™ Total RNA-Seq Kit will detect splicing isoforms, gene fusions, and non-polyadenylated RNAs through full-length transcriptome profiling of up to 100,000 single cells per run. Similarly, the Shasta™ Whole-Genome Amplification Kit will enable novel insights into tumor heterogeneity through copy number variant (CNV) and single nucleotide variant (SNV) analyses of over 1,500 single cells at once.

Takara Bio USA, Inc. today announced that it has once again prevailed in its second patent dispute with Jumpcode Genomics, Inc. The latest result concerns Takara Bio USA’s challenge to the validity of Jumpcode’s granted European patent EP3102722. Following a hearing before the Opposition Division of the European Patent Office on November 28, the European Patent Office revoked Jumpcode’s patent in its entirety, with no claims allowed. This contrasts with Jumpcode’s earlier challenge to Takara Bio USA’s European Patent (EP3105325), which the European Patent Office upheld following a similar hearing last year. In that earlier hearing, the Opposition Division held that Takara Bio USA’s independent Claim 1, the broadest claim in the patent, is valid and should therefore be maintained as originally granted.

Takara Bio USA, Inc., a pioneering life science reagent and instrument company and wholly owned subsidiary of Takara Bio Inc., is partnering with BioExcel Diagnostics to develop and validate a new high-throughput and comprehensive method for detecting syndromic-based infectious diseases. The method employs real-time PCR automation technology and reagents from Takara Bio to detect viruses, bacteria, fungi, and antimicrobial resistance genes specific to the contributing pathogen. Data generated allows clinicians to quickly determine the best route of treatment for their patients.

Takara Bio USA, Inc. (TBUSA) today announced that the European Patent Office has reviewed and confirmed the validity of TBUSA’s granted European patent EP 3105325, entitled “Methods of depleting a target molecule from an initial collection of nucleic acids, and compositions and kits for practicing the same.” TBUSA’s patent was opposed by Jumpcode Genomics, Inc.

Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., today announced the launch of the SMART-Seq® Pro kit for the ICELL8® cx Single-Cell System. This automated single-cell RNA-seq solution allows scientists to generate full-length transcriptome data from over 1,500 single cells simultaneously and from a wide range of sample types—even large, delicate adult cardiomyocytes.